42nd week of 2013 patent applcation highlights part 53 |
Patent application number | Title | Published |
20130274279 | CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4-[2-(PROPAN- E-2-SULFONYL)-PHENYL]-PYRIMIDINE-2, 4-DIAMINE - The present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease. | 2013-10-17 |
20130274281 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN - Provided herein are methods, compositions and kits for the treatment of locally advanced or metastatic breast cancer or breast cancer brain metastases. The method comprises administration of 4-iodo-3-nitrobenzamide, a metabolite or salt thereof in combination with irinotecan. The method of treating locally advanced or metastatic breast cancer comprises at least one 21 day treatment cycle. | 2013-10-17 |
20130274282 | COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN - Pain and/or neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as celecoxib that inhibits the metabolism of dextromethorphan, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein. | 2013-10-17 |
20130274283 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS - Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided. | 2013-10-17 |
20130274284 | PREPARATION OF PRASUGREL HYDROCHLORIDE - The present application relates to process for the preparation of prasugrel, its pharmaceutically acceptable salts, and its intermediates. | 2013-10-17 |
20130274285 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS - The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure | 2013-10-17 |
20130274286 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY - The present invention relates to identification of a compound which inhibits the enzyme NMPRTase and glioma cancer cell growth and further used for glioma therapy. Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes nicotinamide phosphoribosyltransferase (NMPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. PBEF1 transcript and protein levels have been shown to be elevated in glioblastoma and a chemical inhibitor of NMPRTase has been shown to specifically inhibit cancer cells. Here a structure based drug discovery approach has been reported with an aim to develop novel inhibitors for glioblastoma therapy. Present invention relates to virtual screening using docking of ligands from a large library of 13,000 compounds against NMPRTase as the macromolecular target resulting in short listing of 34 possible ligands, of which six were tested experimentally, using the NMPRTase enzyme inhibition assay and further with the glioma cell viability assays. Of these, two compounds were found to be significantly efficacious in inhibiting the conversion of nicotinamide to NAD, and out of which one compound, 3-amino-2-benzyl-7-nitro-4-(2-quinolyl-)-1,2-dihydroisoquinolin-1-one, was found to inhibit the growth of a PBEF1 over expressing glioma derived cell line U87 also. | 2013-10-17 |
20130274287 | PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES - The invention provides novel compounds having the general formula (I) | 2013-10-17 |
20130274288 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 2013-10-17 |
20130274289 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA - Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia. | 2013-10-17 |
20130274290 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS - Disclosed herein are compositions and methods for treating a sigma-2 receptor- mediated condition or disorder, including treating one or more symptoms of a sigma-2 receptor-mediated condition or disorder. | 2013-10-17 |
20130274291 | 3'-DEUTERO-POMALIDOMIDE - The present application describes 3′-deutero-pomalidomide, deuterated derivatives thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2013-10-17 |
20130274292 | Ketoheteroarylpiperdine and -Piperazine Derivatives as Fungicides - Ketoheteroarylpiperidine and -piperazine derivatives of the formula (I), | 2013-10-17 |
20130274293 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY - This invention relates to the use of a ligand of the 5-HT | 2013-10-17 |
20130274294 | 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters - The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it. | 2013-10-17 |
20130274295 | PIOGLITAZONE FOR USE IN THE TREATMENT OF ADRENOLEUKODYSTROPHY - The present invention is directed to pioglitazone, or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising pioglitazone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment and/or prevention of an adrenoleukodystrophy. | 2013-10-17 |
20130274296 | REMELTED INGESTIBLE PRODUCTS - A method of preparing an orally ingestible hard boiled product, comprising: i) heating a sugar material to a first temperature sufficient to liquefy the sugar material; ii) cooling the liquefied sugar material to provide a cooled sugar material having a solid or semi-solid form; iii) heating the cooled sugar material to a second temperature, which is lower than the first temperature; iv) combining the sugar material with one or more temperature sensitive ingredients before, during, or after said heating step iii), but after said cooling step ii), such that an intimate mixture of the second liquefied sugar material and the one or more temperature sensitive ingredients is provided; and v) cooling the intimate mixture to form an orally ingestible product. Orally ingestible hard boiled products prepared according to this method are also provided. | 2013-10-17 |
20130274297 | PHARMACEUTICAL COMPOSITES OF POORLY WATER SOLUBLE DRUGS AND POLYMERS - The invention provides a composite of drug, polymeric carrier and at least one not cross linked polymer useful to improve the solubility of poorly water soluble drugs. The present invention comprises manufacturing process of this composite material. The manufacturing process is carried out by the solvent induced activation process, wherein the not cross-linked polymer is loaded into the composite from organic solution, possibly together with the drug. Pharmaceutical compositions comprising said composite in combination with pharmaceutical acceptable excipients are also described herein. | 2013-10-17 |
20130274298 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS - This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII. This invention also refers to a pharmaceutical composition comprising at least one of the azole compounds represented by the general formula VIII, to the use of such compositions and to methods of treatment or inhibition of tuberculosis and leishmaniasis. | 2013-10-17 |
20130274299 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating - The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions. | 2013-10-17 |
20130274300 | Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof - An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch. | 2013-10-17 |
20130274301 | Novel Use of Leflunomide and Malononitrilamides - The invention relates to the use of polycycloolefins in electronic devices and more specifically to the use of such polycycloolefins as interlayers applied to insulating layers used in electronic devices, the electronic devices that encompass such polycycloolefin interlayers and processes for preparing such polycycloolefin interlayers and electronic devices. | 2013-10-17 |
20130274302 | TOPICAL LOCALIZED ISOXAZOLINE FORMULATION COMPRISING GLYCOFUROL - This invention provides topical localized formulations comprising an isoxazoline compound and a pharmaceutically or veterinary acceptable liquid carrier vehicle comprising glycofurol and an improved method for controlling, and preventing parasite infestation in animals. | 2013-10-17 |
20130274303 | METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION - The present disclosure relates to methods of treating a stimulant addiction of a patient comprising administering to a patient in need a therapeutically effective dose of a selective dopamine beta-hydroxylase inhibitor thereby decreasing stimulant reward, inducing aversion for the stimulant or preventing relapse in the patient. The disclosure further encompasses methods whereby a therapeutically effective dose of a selective dopamine beta-hydroxylase inhibitor is determined by: characterizing the genetic profile of the patient with respect to the gene encoding dopamine beta-hydroxylase, a polymorphism therein correlating to the level of endogenous dopamine beta-hydroxylase activity in the patient before administering the therapeutic agent. | 2013-10-17 |
20130274304 | Chemical Compounds - Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts. | 2013-10-17 |
20130274305 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS - The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art. The present invention relates to novel nitroimidazole derivates represented by formula (1). | 2013-10-17 |
20130274306 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS - The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity. | 2013-10-17 |
20130274307 | COMPOSITIONS COMPRISING ABSCISIC ACID AND A FUNGICIDALLY ACTIVE COMPOUND - The present invention relates to methods comprising applying to a useful plant, the locus thereof or propagation material thereof a combination of abscisic acid and a fungicidally active compound, which fungicidally active compound is a succinate dehydrogenase inhibitor, in particular for increasing the potency of a fungicidally active compound. The invention also relates to compositions comprising abscisic acid and the fungicidally active compounds as well as seeds comprising the combinations. | 2013-10-17 |
20130274308 | MODULATION OF FACTOR 11 EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism. | 2013-10-17 |
20130274309 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES - The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes. The compositions and methods of the invention are utilized to effect the oral, buccal, rectal or vaginal administration of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic, palliative or prophylactic purposes | 2013-10-17 |
20130274310 | RNAi MODULATION OF SCAP AND THERAPEUTIC USES THEREOF - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell. | 2013-10-17 |
20130274311 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell. | 2013-10-17 |
20130274312 | siRNA Against p22phox - The invention relates to siRNA against p22phox, compositions comprising the siRNA, methods of treating diseases with the siRNA and cell based systems for studying the effect of p22 phox modulation by siRNA or cells. | 2013-10-17 |
20130274313 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 2013-10-17 |
20130274314 | MITOCHONDRIAL TARGETED RNA EXPRESSION SYSTEM AND USE THEREOF - Described herein is a mitochondrial-targeted RNA expression system (mtTRES) for delivery of RNA molecules to mitochondria. mtTRES vectors generate RNAs in vivo that are un-capped, non-polyadenylated, and actively directed to mitochondria. The disclosed vectors are capable of delivering either non-coding RNA molecules or RNA molecules encoding a protein of interest to the mitochondria. In particular, the disclosed vectors include (1) an RNAPIII initiation (promoter) sequence, (2) a non-coding leader sequence (NCL), (3) a mitochondrial translation initiation sequence and an ORF encoding a protein of interest, or a sequence encoding a non-coding RNA, and (4) an RNAPIII termination sequence. | 2013-10-17 |
20130274315 | PRO-ANGIOGENIC GENES IN OVARIAN TUMOR ENDOTHELIAL CELL ISOLATES - A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject. | 2013-10-17 |
20130274316 | MUC1 AND GALECTIN-3 - The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and galectin-3. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of galectin-3 by a cell. | 2013-10-17 |
20130274317 | DERIVATIVES OF SMALL INTERFERING RNAS AND USE THEREOF - The present invention relates to a small interfering RNA (siRNA) being 2′-O-methyl modified and there being attached thereto by a phosphodiester bond a position 3′, wherein group R in position 3′, wherein R is selected from among: a C | 2013-10-17 |
20130274318 | Novel Method of Protecting Islet Cells From Apoptosis during the Donor Harvesting Process - The present invention relates to methods for improving the viability and recovery of islets that are separated from a donor organ for subsequent transplantation and more particularly relates to the use of eIF-5A1 siRNAs to enhance the viability of islets. | 2013-10-17 |
20130274319 | INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT - The invention relates to an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device. In order to increase the bio-compatibility of this device, it is provided with at least one coating. The coating contains a therapeutic agent which is comprised in a matrix that sticks to the intraluminal device. Instead of being formed by a little bio-compatible polymer, the matrix is formed by a bio-compatible oil or fat, such as cod-liver oil or olive oil. Preferably, the bio-compatible oil or fat further comprises alfa-tocopherol. | 2013-10-17 |
20130274320 | Chromone Inhibitors of S-Nitrosoglutathione Reductase - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2013-10-17 |
20130274321 | Topical Compositions with Cannabis Extracts - The present invention provides a method for a topical treatment of a skin cyst. The method includes: applying a formulation to the skin cyst of a mammal; wherein the formulation includes: a dimethyl sulfoxide extract of mature, dried, powdered | 2013-10-17 |
20130274322 | Process for the Synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isoben- zofuran-1,9'-xanthen]-3-one(Rose Bengal) and Related Xanthenes - A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments. | 2013-10-17 |
20130274323 | METHOD OF INHIBITING ABCG2 AND OTHER TREATMENT METHODS - Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): | 2013-10-17 |
20130274324 | COMPOSITIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS CONTAINING PLANT PROTEIN-SOY POLYSACCHARIDE COMPLEXES - The present invention relates to compositions comprising a) 0.1 to 70 weight-% based on the composition of one or more fat-soluble active ingredients; b) one or more plant protein(s) chosen from the group of proteins suitable for food application; and c) one or more soy soluble polysaccharide(s); wherein the sum of the amount of protein(s) and the amount of polysaccharide(s) represents 10 to 85 weight-% based on the composition in dry matter and, wherein the weight ratio of protein(s) to polysaccharide(s) is chosen like 1:b with the proviso that b is comprised between 0.5 and 15. | 2013-10-17 |
20130274325 | Fluorinated Benzofuran Derivatives - The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described. | 2013-10-17 |
20130274326 | EXTRACT OF EUODIA SUAVEOLENS SCHEFF, REPELLENT COMPOSITIONS AND USE THEREOF - The invention relates to an extract of | 2013-10-17 |
20130274327 | NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID - The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations. | 2013-10-17 |
20130274328 | FERRIC CITRATE DOSAGE FORMS - Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder). | 2013-10-17 |
20130274329 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES - Compounds selected from the group of N-unsubstituted or N-alkylated or N-acylated 14-O-[(amino(C | 2013-10-17 |
20130274330 | ORAL DOSAGE FORM - An oral dosage form of entacapone and methods for the preparation thereof are provided. | 2013-10-17 |
20130274331 | Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent - Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a urate-lowering agent and an anti-inflammatory agent. In some aspects the urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second agent is an anti-inflammatory agent, or a pharmaceutically acceptable salt thereof. | 2013-10-17 |
20130274332 | OPHTHALMIC COMPOSITION FOR CONTACT LENS - An object of the present invention is to provide an ophthalmic composition for contact lens that can inhibit bacterial adhesion to a contact lens. | 2013-10-17 |
20130274333 | CORIOLUS VERSICOLOR EXTRACTS, METHODS OF ISOLATING BIOLOGICALLY-ACTIVE COMPOUNDS, AND USES THEREOF - The subject invention provides efficient and convenient methods of isolating 9-oxo-10E, 12E-octadecadienoic acid methyl ester (9-KODE methyl ester) from | 2013-10-17 |
20130274334 | SULFOPEROXYCARBOXYLIC ACIDS, THEIR PREPARATION AND METHODS OF USE AS BLEACHING AND ANTIMICROBIAL AGENTS - The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents. | 2013-10-17 |
20130274335 | Pet Food Compositions and Methods for Treating Arthritis and Inflammation Associated with Arthritis - The present invention provides food compositions that are effective in treating arthritis or inflammation associated with arthritis in a companion animal, preferably a canine or feline. | 2013-10-17 |
20130274336 | TRANS10:CIS12 ISOMER OF CONJUGATED LINOLEIC ACID AS A THERAPEUTIC AND PREVENTATIVE AGENT FOR HYPERTENSION SPECIFIC TO PREGNANCY - Described herein are compositions and methods for the use of t10:c12 conjugated linoleic acid to reduce hypertension in pregnant women. Advantageously, by reducing blood pressure, the compositions will also reduce the risk of pre-term birth. The t10:c12 conjugated linoleic acid compositions are advantageously food products, particularly dairy products. Also included are methods of determining the t10:c12 conjugated linoleic acid content of a dairy product and optionally enriching the dairy product for t10:c12 conjugated linoleic acid. Enriched dairy products can be labeled for use during pregnancy. | 2013-10-17 |
20130274337 | USE OF DHA, EPA OR DHA-DERIVED EPA FOR TREATING A PATHOLOGY ASSOCIATED WITH CELLULAR OXIDATIVE DAMAGE - The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise. | 2013-10-17 |
20130274338 | PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF REDUCING SEBUM PRODUCTION USING SAME - The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production. | 2013-10-17 |
20130274339 | NOVEL FUNCTIONAL FOOD PRODUCT AND METHOD THEREOF - A whole impregnated freeze dried food product for delivering a material of interest comprising;
| 2013-10-17 |
20130274340 | BUFFER SOLUTIONS HAVING SELECTIVE BACTERICIDAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND METHODS OF USING SAME - Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided. | 2013-10-17 |
20130274341 | Methods and Compositions for Treatment of Dermal Conditions - The present invention comprises methods and compositions for the treatment of pathological conditions of the dermis and dermal structures of animals and humans. In particular, the present invention comprises the use of topical delivery vehicles, including hydrogels, which incorporate active agents such as organic acids, for the treatment of dermal conditions. | 2013-10-17 |
20130274342 | COMPOSITIONS AND METHODS FOR TREATING COUGH - Compositions, methods of making compositions and methods of treating cough are described herein. In some embodiments, the compositions are lozenges comprising memantine and an alkalinizing agent. | 2013-10-17 |
20130274343 | Water Soluble Composition Comprising Curcumin Having Enhanced Bioavailability and Process Thereof - The invention disclosed relates to a water-soluble composition having enhanced bioavailability useful for the treatment of depression which comprises a synergistic combination of curcumin, at least an antioxidant, a hydrophilic carrier and a fat. The invention also discloses a process for the preparation of the curcumin composition which comprises the steps of dissolving curcumin, at least one antioxidant, a hydrophilic carrier and a fat in a solvent to form a homogenous mass; warming the resultant mass at a temperature ranging from 25° C. to 60° C. for a period of 4 to 8 hours to obtain a dry wet mass; removing the solvent by evaporation to form dry mass and pulverizing the dry mass to form a fine powder. | 2013-10-17 |
20130274344 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF - The presently disclosed and claimed inventive concept(s) provides new estrogenic compounds of the general formula | 2013-10-17 |
20130274345 | Antimicrobial Composition Having Skincare Properties - The invention relates to an antimicrobial composition which contains 80-95% by weight of ethanol 1-propanol, 2-propanol or the fixtures thereof. The hydroalcoholic composition according to the invention is preferably used, in hand disinfectants. Due to the oil components contained therein it is skin-friendly and has good skin care properties, thus making it possible to combine good disinfectant properties with good use properties and skin-friendliness. | 2013-10-17 |
20130274346 | PHARMACOLOGICALLY OPTIMIZED MULTIMODAL DRUG DELIVERY SYSTEM FOR NORDIHYDROGUIARETIC ACID (NDGA) - The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof. | 2013-10-17 |
20130274347 | Fungicidal and Parasiticidal Fire-Retardant Powder - Fire-retardant powder comprising at least 30% by weight of Lewis acid, at least 5% by weight of alkaline bicarbonate, and at least 3% by weight of silica, and method of manufacturing such fire-retardant powder. A building material preferably comprising natural fibers and comprising at least 5% by weight and at most 30% of such powder. | 2013-10-17 |
20130274348 | ORALLY DISINTEGRATING TABLET - It is an object of the present invention to provide an orally disintegrating tablet that has desirable oral disintegrability and excellent tablet hardness, a process for producing the same, and the like. | 2013-10-17 |
20130274349 | OPEN-CELLED FOAM WITH SUPERABSORBENT MATERIAL AND PROCESS FOR MAKING THE SAME - The present invention relates to an open-celled foam comprising: (a) an aqueous-based polymer dispersion, said polymer dispersion comprising a polyethylene copolymer and an ethylene-acrylic acid copolymer; and (b) from about 5% to about 15% of a foaming composition, said foaming composition comprising at least a foaming agent and a stabilizing agent; further comprising a particulate superabsorbent polymer material within the voids and pores of said open-celled foam and the method of making the same. | 2013-10-17 |
20130274350 | NOVEL SWEETENER HAVING SUCROSE-LIKE TASTE, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME - To develop a method for producing a novel sweetener containing glucose, fructose, and psicose, which is produced from glucose liquid sugar using an isomerase and an epimerase; use of the novel sweetener as a food or drink material; and a novel sweetener capable of preventing obesity caused by the intake thereof. An isomerase and an epimerase are allowed to act on glucose liquid sugar produced in a glucose liquid sugar production plant to thereby produce D-psicose, thereby providing a novel sweetener (product) that maintains the degree and quality of sweetness of a glucose-fructose mixed solution and never causes obesity, a method for producing the same, and use of the same. | 2013-10-17 |
20130274351 | HIGHLY SOLUBLE REBAUDISIDE D - The invention relates to a process for producing highly soluble compositions containing purified steviol glycosides from | 2013-10-17 |
20130274352 | Oral Drug Devices and Drug Formulations - Compositions containing a drug to be delivered and at least one chemical permeation enhancer (CPE), and methods of making and using these compositions are described herein. In a preferred embodiment, the compositions contain two or more CPEs which behave in synergy to increase the permeability of the epithelium, while providing an acceptably low level of cytotoxicity to the cells. The concentration of the one or more CPEs is selected to provide the greatest amount of overall potential (OP). Additionally, the CPEs are selected based on the treatment. CPEs that behave primarily by transcellular transport are preferred for delivering drugs into epithelial cells. CPEs that behave primarily by paracellular transport are preferred for delivering drugs through epithelial cells. Also provided herein are mucoadhesive oral dosage forms. In a preferred embodiment, the oral dosage form is a multi-compartmental device, containing (i) a supporting compartment, (ii) drug compartment and (iii) mucoadhesive compartment. | 2013-10-17 |
20130274353 | SYSTEM AND METHOD FOR GENERATION OF EMULSIONS WITH LOW INTERFACIAL TENSION AND MEASURING FREQUENCY VIBRATIONS IN THE SYSTEM - A method and apparatus for generating droplets with a high level of uniformity in liquid systems that present a low interfacial tension. This method and apparatus utilize the breakup of the dispersed phase in a controlled fashion by periodically varying the pressure that drives the fluids so as to successfully generate emulsions with a good control over the size. The method and apparatus can be used for the formation of simple emulsion or double emulsion where a larger droplet contains one or more smaller droplets. | 2013-10-17 |
20130274354 | METHOD OF PRODUCING SUBSTITUTE NATURAL GAS - Provided is a method of producing a substitute natural gas. The method includes: generating carbon monoxide and hydrogen using coal and a metal fuel; and generating methane from the generated carbon monoxide and hydrogen. Since the method supplies a metal fuel along with coal, generates hydrogen from the metal fuel, and supplies the hydrogen, the amount of coal needed to generate methane through methanation may be reduced and the amount of carbon dioxide (CO | 2013-10-17 |
20130274355 | CATALYST USEFUL IN FISHER-TROPSCH SYNTHESIS - The present invention relates to a catalyst composition comprising cobalt manganese oxide which is modified with lanthanum and/or phosphorus and optionally one or more basic elements selected from the group consisting of alkali metal, alkaline earth metal and transition metal. Furthermore, a method for preparing said catalyst composition and a process for producing aliphatic and aromatic hydrocarbons by Fischer-Tropsch synthesis using said catalyst composition is provided. | 2013-10-17 |
20130274356 | ENHANCED CONVERSION OF SYNGAS TO PROPYLENE - Conversion of synthesis gas to propylene is enhanced via a stepped process wherein a Fischer-Tropsch reaction is first carried out, followed by recovery of propylene produced thereby and then use of product ethylene and unreacted syngas in a hydroformylation reaction to produce propanol, which is then dehydrated to form additional propylene. The process enables significant enhancement of propylene yield that is efficient and makes use of ethylene that is a byproduct of Fischer-Tropsch processes that are employed primarily for production of higher olefms, such as hexene and octene. Thus, it can be carried out in conjunction with already on-line Fischer-Tropsch facilities. | 2013-10-17 |
20130274357 | HYBRID ANION EXCHANGER IMPREGNATED WITH HYDRATED ZIRCONIUM OXIDE FOR SELECTIVE REMOVAL OF CONTAMINATING LIGAND AND METHODS OF MANUFACTURE AND USE THEREOF - Polymeric anion exchanger are used as host materials in which sub-micron sized hydrated Zr(IV) oxides (HZrO) particles are irreversibly dispersed within the ion exchange medium, such as beads or fibers. The HZrO can be impregnated into the pore structure of resin by mixing the parent anion exchange resin with zirconium solution prepared by pre-calcined zirconium oxide dissolved in concentrated mixture of alcohol and acid, and then followed by precipitation of HZrO particles within the resin by using alkaline solution. Since the anion exchangers have positively charged such as quaternary ammonium functional groups, anionic ligands such as arsenate, fluoride can transport in and out of the gel phase without subjected to the Donnan exclusion effect. Consequently, anion exchanger-supported HZrO submicron particles exhibit significantly greater capacity to remove arsenic and fluoride in comparison with parent anon exchange resins. Known cation exchange resins as support materials do not offer high arsenic or fluoride removal capacity. | 2013-10-17 |
20130274358 | METHOD FOR PRODUCING POLYETHER POLYOL AND METHOD FOR PRODUCING RIGID FOAM SYNTHETIC RESIN - To provide a method for producing a polyether polyol having a low viscosity and little odor, whereby when a rigid foam synthetic resin is produced, good strength and flame retardancy can be obtained. A method for producing a polyether polyol, which comprises ring-opening addition of an alkylene oxide to an initiator obtainable by reacting a phenol, an aldehyde and an alkanolamine, and which comprises a first step of ring-opening addition of at least one member selected from propylene oxide and butylene oxide to the initiator in the absence of a catalyst, and a second step of ring-opening addition of an alkylene oxide of which at least a part is ethylene oxide, to a reaction product of the first step, in the presence of a catalyst, wherein the proportion of ethylene oxide in the total amount of the alkylene oxide to be added to the initiator, is from 5 to 95 mol %. | 2013-10-17 |
20130274359 | CONTINUOUS METHOD FOR PRODUCING SOLID, HOLLOW OR OPEN PROFILES - Disclosed herein is a method for producing a polystyrene foam. The polystyrene is dosed with a gas and the polystyrene and gas are mixed in an extruder in order to obtain a homogenous mixture. The homogeneous mixture is cooled as it travels through the extruder and is then extruded from the die at a pressure of less than 7 MPa to form a foam with a smooth skin. | 2013-10-17 |
20130274360 | ACTIVATED RESOL CURE RUBBER COMPOSITION - The invention is related to a process for preparing a vulcanizable rubber composition comprising at least one elastomeric polymer, at least one phenol formaldehyde resin cross-linker, an activator package, and at least one activated zeolite, and a vulcanizable rubber composition prepared by said process. | 2013-10-17 |
20130274361 | PRESSURE-SENSITIVE ADHESIVE SHEET AND PRESSURE-SENSITIVE ADHESIVE COMPOSITION - A pressure-sensitive adhesive sheet according to an embodiment of the present invention has a pressure-sensitive adhesive layer including an acrylic polymer. This acrylic polymer contains, as monomer components, an acrylic monomer not containing a polar group (A) and a polar group-containing monomer (B). The 100% modulus of this pressure-sensitive adhesive layer is 20 to 200 N/cm | 2013-10-17 |
20130274362 | HYDROGELS THAT UNDERGO VOLUMETRIC EXPANSION IN RESPONSE TO CHANGES IN THEIR ENVIRONMENT AND THEIR METHODS OF MANUFACTURE AND USE - Hydrogels are described that expand volumetrically in response to a change in their environment and as well as their methods of manufacture and use. | 2013-10-17 |
20130274363 | HYDROPHILIC POLYURETHANE FOAM - A method for making hydrophilic polyurethane foam includes providing methylene diphenyl diisocyanate, mixing polyether polyols with the methylene diphenyl diisocyanate, and allowing the methylene diphenyl diisocyanate and the polyether polyols to form the hydrophilic polyurethane foam. The hydrophilic polyurethane foam has a content of ethylene oxide that is between about 30-100% by weight. The methylene diphenyl diisocyanate and polyols are mixed in a one-stage process. The hydrophilic polyurethane foam absorbs water in time period that is less than about 30 seconds. | 2013-10-17 |
20130274364 | SELF-CRUSHING POLYURETHANE SYSTEMS - Embodiments of the invention provide for polyurethane flexible foams that do not require a post production crushing step. These “self crushing” flexible foams neither collapse, skin peel, nor form voids upon demolding, and yet maintain excellent physical properties such as uniform cell sizes, high quality surface appearance, compression set, resistance to fatigue, etc. | 2013-10-17 |
20130274365 | POLYURETHANE WITH IMPROVED ABRASION RESISTANCE, THE METHOD FOR PREPARING THE SAME AND USE THEREOF - The present invention relates to a polyurethane with improved abrasion resistance. The reaction components comprise a certain content of polyisoprene. The polyurethane presented in this invention possesses improved abrasion resistance and good surface quality. | 2013-10-17 |
20130274366 | FLEXIBLE UV CURABLE COATING COMPOSITIONS - Disclosed herein are ultraviolet (UV) curable coating compositions that provide transparent, flexible, and abrasion-resistant coatings when cured on a substrate. The coating compositions comprise an adduct of a multifunctional acrylate monomer component and an amino-organofunctional silane; an organic solvent component; an acid; a colloidal silica component; and a multifunctional urethane acrylate oligomer component. The amino-organofunctional silane is represented by the formula X | 2013-10-17 |
20130274367 | SURFACE MODIFICATION METHOD, SURFACE-MODIFIED ELASTIC BODY, GASKET FOR INJECTOR, INJECTOR, AND TIRE - Provided are: surface modification method for imparting slidability to surface of elastic body such as vulcanized rubber or thermoplastic elastomer without using expensive self-lubricating resin; surface-modified elastic body with polymer brush formed on its surface; and gasket for injector and injector formed of surface-modified elastic body. The surface modification method applies to surface of thermoplastic elastomer or vulcanized rubber. The surface modification method comprises the step of forming hydroxyl group on surface of to-be-modified object such as rubber so that water contact angle of the surface becomes 8 to 50 degrees smaller than original water contact angle in unmodified condition, the step of forming polymerization initiation site by subjecting the hydroxyl group to action of secondary or tertiary organic halide, and the step of growing polymer brush on the surface of to-be-modified object by subjecting monomer to radical polymerization at the polymerization initiation site acting as a point of initiation. | 2013-10-17 |
20130274368 | Continuous Process For Esterifying Polymers Bearing Acid Groups - The invention accordingly provides a continuous process for reacting synthetic poly(carboxylic acid)s (A) containing, per polymer chain, at least 10 structural repeat units of formula (I) | 2013-10-17 |
20130274369 | NEW CATIONIC POLYMERS - New water soluble cationic copolymers derived from N-vinyl amide monomers and ethylenically unsaturated compounds bearing cationic groups. | 2013-10-17 |
20130274370 | POLYMER FOR CONTACT LENSES - The present invention relates to a polyurethane polymer composition prepared by reacting a mixture comprising: a} at least one polyethylene glycol, and either b) at least one poly-isocyanate, having a functionality greater than 2 or c) at least one di-isocyanate and at least one polyol or at least one macropolyol having a functionality greater than 2, wherein the polyol or macropolyol is present at an amount of 0.1 to 9 wt % of the mixture. The invention also relates to a process for preparing a polyurethane xero-gel in the form of a moulded article, said process comprising the steps of: i.) preparing said mixture; ii. ) dispensing the reaction mixture formed in step i) into a mould; iii. ) allowing the reaction mixture to react and cure; iv. ) removing the moulded article from the mould; and v. ) hydrating the moulded article. | 2013-10-17 |
20130274371 | Silicone Hydrogels and Methods of Manufacture - Embodiments of silicone hydrogels, ophthalmic lenses made therefrom, and methods of making the same are described. Fully hydrated silicone hydrogels have relatively high water content and oxygen permeability, along with relatively low modulus of elasticity. Embodiments of the silicone hydrogels in substantially dehydrated condition are adapted to lathe cutting at or above room temperature. Variations of the silicone hydrogels include silicon-containing monomers in an amount of 7.5% or greater by weight, a hydrophilic substituted N-vinyl acetamide monomer, and a hydrophilic non-acetamide monomer in an amount resulting in a hydrophilic substituted N-vinyl acetamide monomer to hydrophilic non-acetamide monomer weight to weight ratio of greater than 2.1 to 1 | 2013-10-17 |
20130274372 | ANTIMICROBIAL CHEMICAL COMPOSITIONS - Antimicrobial chemical compositions comprise an aluminum phosphate (AlP) solid dispersed within a binding polymer, wherein one or more bioactive materials are disposed within AlP forming a bioactive-AlP complex. The complex may comprise the bioactive material chemically bonded with the AlP, physically combined with the AlP, or a combination of both. The complex may be formed according to precipitation, condensation and sol-gel methods of forming. The complex is engineered to provide a controlled delivery of the bioactive material or a constituent thereof upon exposure to moisture to give a desired level of antimicrobial resistance to a film or composite formed from the composition of at least about 30 μg/m | 2013-10-17 |
20130274373 | BIODEGRADABLE RESIN COMPOSITION - The present invention is a biodegradable resin composition comprising a sparingly hydrolyzing biodegradable resin (A) and an ester decomposition promoter (B), the ester decomposition promoter (B) being a copolymerized polyester that contains a segment (X) of a sparingly hydrolyzing polyester and a segment (Y) of an easily hydrolyzing polyester at a weight ratio of 10/902013-10-17 | |
20130274374 | RUBBER COMPOSITIONS CONTAINING NON-SULFUR SILICA COUPLING AGENTS BOUND TO DIENE RUBBERS - The invention provides vulcanizable rubber compound having improved tensile mechanical and dynamic viscoelastic properties. The compounds are formed by mixing an elastomer, containing unsaturated carbon-carbon bonds in its molecular structure, with a reinforcing inorganic filler silica in the presence of an alkyl alkoxysilane and a non-sulfur coupling agent that binds to the rubber backbone with an “ene” linkage or a 1,3 dipolar addition linkage. In particular, the coupling agent and the alkyl alkoxysilane are present in the compound in a weight ratio of about 0.0001:1 to about 1:1. | 2013-10-17 |
20130274375 | RUBBER COMPOSITION AND METHOD OF PRODUCING SAME, AND TIRE - The present invention provides a rubber composition that comprises a rubber component containing a polybutadiene and a dienic rubber or an olefinic rubber immiscible with the polybutadiene, and a filler, in which the Mooney viscosity (ML | 2013-10-17 |
20130274376 | SURFACE COATING AND FUSER MEMBER - The present teachings disclose a surface coating composition. The surface coating composition includes fluorine containing particles, aerogel particles and positive tribocharging particles. The surface coating is useful as the release layer for fuser members. | 2013-10-17 |
20130274377 | Modeling compounds and methods of making and using the same - Modeling compounds and methods for making the same are described. The modeling compounds, in some embodiments, comprise about 20% to about 40% by weight starch-based binder, and about 0.15% to about 1.2% by weight microspheres dispersed throughout the compounds. In some embodiments, the modeling compound further comprises vinylpyrrolidone polymers. | 2013-10-17 |
20130274378 | METHOD FOR PRODUCING FLAME-PROOFED THERMOPLASTIC MOLDING COMPOUNDS - The invention relates to a method for producing thermoplastic molding compounds, comprising: A) 40 to 99 wt % of at least one thermoplastic polymer, B) 1 to 60 wt % of a flame-proofing agent component containing an expandable graphite, and C) 0 to 60 wt % of further additives, by melt-mixing components A), B) and C) in a screw-type extruder, wherein the screw-type extruder, along the feed direction, comprises, in the following order, at least one dosing zone, a plastifying zone, a homogenizing zone, a second dosing zone, and a discharge zone, in that the dosing takes place into the screw-type extruder having the length L, wherein the length L is defined as the section starting with the first dosing unit for adding components A, B and/or C and ending, in the feed direction, at the discharge opening, a melt is generated after adding components A, B and C in the range of 0 liter to 0.15 liter in a first method step in the presence of component B1), and in a second method step, after the addition of component B1) in the range of 0.5 liter to 0.95 liter, component B1) is mixed into said melt, wherein said method offers technical advantages. | 2013-10-17 |
20130274379 | POLYMER CONCRETE COMPOSITION - A curable composition for polymer concrete including (A) at least one epoxy resin composition comprising (A1) at least one epoxy resin, and (A2) at least one divinylarene dioxide; and (B) at least one hardener composition; wherein the divinylarene dioxide is present in the epoxy resin composition in a sufficient concentration such that the divinylarene dioxide reduces the viscosity of the curable composition and provides the necessary properties for cured polymer concrete product made from the curable composition. The divinylarene dioxide reduces the viscosity of the curable composition and, at the same time, provides the necessary properties for polymer concrete applications; and the divinylarene dioxide helps to increase heat deflection temperature (HDT) of the polymer concrete and improves the dimensional stability of a large polymer concrete part without sacrificing any of the other properties of the polymer concrete. | 2013-10-17 |